Navigation Links
Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial
Date:9/19/2008

Rapid Seasonal influenza VLP vaccine trial enrollment positions Company to

report top line data in fourth quarter of this year

ROCKVILLE, Md., Sept. 19 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today it has completed enrollment of healthy volunteers in a Phase IIa clinical trial of its virus-like particle (VLP) based seasonal influenza vaccine. The Phase IIa randomized, placebo controlled clinical trial is evaluating the safety and immunogenicity of different doses of its seasonal influenza VLP vaccine. Specifically, the vaccine will be studied in approximately 300 healthy adults between the ages of 18 and 49 years, who will receive a single injection of either a placebo or an influenza vaccine at doses of 5 mcg, 15 mcg or 30 mcg. The goals of the study are to select a dose for evaluation in a subsequent Phase III efficacy study and to continue the evaluation of safety of its novel influenza VLP vaccines.

VLPs are recombinant structures that mimic the size and shape of a virus but lack genetic material and are therefore incapable of replication. Because they resemble actual infectious particles presenting proteins in the same conformation as on the wild-type virus, they are able to induce potent immune response. Novavax's VLP vaccine may be differentiated from other influenza vaccines in several ways. First, it includes three viral proteins important for inducing a broad immune response including two surface proteins, hemmaglutinin ("HA") and neuraminidase ("NA"), and a core matrix protein, M1. In contrast, most seasonal vaccines consist almost entirely of HA with little or no NA and M1. The HA protein induces antibody that neutralizes or blocks the growth of the virus; NA induces antibodies
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Novavax Commences Clinical Testing of its Seasonal Influenza VLP Vaccine Candidate
2. Novavax Announces Closing of $18 Million Registered Direct Offering
3. Novavax Announces Pricing of $18 Million Financing of Common Stock and Warrants
4. Novavax to Join Russell 3000 Index
5. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
6. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
7. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
8. Novavax Reports First Quarter 2008 Financial Results
9. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
10. Novavax Opens Its First U.S. Vaccine Plant
11. Novavax CEO to Present at the World Vaccine Congress 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... DIEGO, Aug. 29, 2014  Pfenex Inc. (NYSE ... the development of high-value and difficult to manufacture ... update and reported financial results for the second ... the successful completion of our initial public offering, ... our biosimilar product candidates, derived from our proprietary ...
(Date:8/29/2014)... of the most promising technologies for future quantum circuits ... instead of electrons. First, it is necessary to be ... control their direction. Researchers around the world have made ... now scientists at the Niels Bohr Institute have succeeded ... at a time and in a particular direction. The ...
(Date:8/29/2014)... New York (PRWEB) August 29, 2014 ... valued at $5.6 billion in 2019. It is ... from 2013 to 2019, and was valued at ... report published by Transparency Market Research. , For ... visit: http://www.transparencymarketresearch.com/companion-diagnostics-market.html . , The research report, ...
(Date:8/29/2014)... According to a new market report published by Transparency ... valued at USD 3,754.6 million in 2012 and is estimated ... CAGR of 5.9% from 2013 to 2019. , Nearly half ... by bone and joint disorders, and this number is expected ... will continue to increase the demand for orthobiologics. Other factors ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Breakthrough in light sources for new quantum technology 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 2Companion Diagnostics Market to Hit $5.6 Billion in 2019: Transparency Market Research 3Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 2Global Orthobiologics Market to Reach $5,519.9 Million by 2019: Transparency Market Research 3
... significant contract with Major Biopharmaceutical CompanyBELGIUM, Wis., March ... is pleased to announce that its subsidiary, Modular ... MPS BioPharm to better reflect its vision, and ... from a major global biopharmaceutical and consumer health ...
... Berkeley -- As synthetic biologists cram more and ... organisms produce ever more complex drugs and chemicals, ... step further. , They have assembled different types ... can perform functions such as secreting and responding ...
... Alternext US: CXM) today announced the completion of a $3.5 ... warrants to purchase shares of common stock. Empire Asset Management ... the transaction. The material terms of the credit facility ... on Form 8-K to be filed with the Securities and ...
Cached Biology Technology:Mach One Subsidiary Modular Process Constructors LLC Changes Name to MPS BioPharm to Better Reflect its Vision 2Assembling cells into artificial 3-D microtissues, including a tiny gland 2Assembling cells into artificial 3-D microtissues, including a tiny gland 3Cardium Completes $3.5 Million Credit Facility 2Cardium Completes $3.5 Million Credit Facility 3Cardium Completes $3.5 Million Credit Facility 4
(Date:8/29/2014)... made some surprising discoveries about the body,s initial ... (SIV), the team found that specialized cells in ... to viral invasion and are the source of ... beta (IL-1β). , Though aimed at the ... gut epithelium that provides a barrier to protect ...
(Date:8/29/2014)... ANTONIO (Aug. 29, 2014) Scientists at the Barshop ... School of Medicine at the UT Health Science Center ... in the tissues of the longest-lived rodent, the naked ... in the cells of naked mole rats protects and ... for damaged and obsolete proteins. , The factor also ...
(Date:8/29/2014)... Until recently, little has been known about what genetic ... team of scientists, one of whom is a University ... showing that genes controlling the development of the brain ... domestication., The study was published Aug. 28 in ... It is online at http://www.sciencemag.org/ ., The domestication ...
Breaking Biology News(10 mins):The early cost of HIV 2Factor in naked mole rat's cells enhances protein integrity 2New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3
... published research has hinted at the connection between the ... athletic African-American males, which was initially observed in black ... the first sizeable patient series definitively confirms this risk ... cell trait, for which all U.S. African Americans are ...
... (FY) 2013 appropriations bill adopted by the House Labor, ... Subcommittee on July 18th fails short of the needed ... Health (NIH) and will delay efforts to improve the ... protect the nation against new and emerging health threats. ...
... inconspicuously lives in our bodies until it senses that ... the offensive. The fungus, known for causing yeast and other ... in immunocompromised patients. An in vivo study, published in ... between a healthy and an unhealthy host and alter its ...
Cached Biology News:Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 2Sickle cell trait can cause sudden cardiac death in black athletes: Why is this controversial? 3House funding bill will delay research progress and place new burdens on NIH 2How a common fungus knows when to attack 2
Request Info...
... the 4300 System features Saga GT , ... SagaGT automates electrophoresis, lane finding, location of ... scoring. ,Saga GT is second generation ... was initially developed at the University of ...
... Polynucleotide Kinase (PNK) catalyzes the transfer ... the 5'-hydroxyl of single- and double-stranded ... enzyme also removes the 3'-phosphate from ... 3', 5'-diphosphates to form a 3'-hydroxyl ...
Request Info...
Biology Products: